An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.

@article{Kamatani2011AnAM,
  title={An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.},
  author={Naoyuki Kamatani and Shin Fujimori and Toshikazu Hada and Tatsuo Hosoya and Kenjiro Kohri and Toshitaka Nakamura and Takanori Ueda and Tetsuya Yamamoto and Hisashi Yamanaka and Yuji Matsuzawa},
  journal={Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases},
  year={2011},
  volume={17 4 Suppl 2},
  pages={S44-9}
}
BACKGROUND Allopurinol has been widely used for the treatment of hyperuricemia, however, it may be associated with various adverse effects. Febuxostat has been identified as a potentially safe and efficacious alternative. OBJECTIVES Febuxostat was administered to patients with hyperuricemia including gout in Japan to compare its efficacy and safety with those of allopurinol. METHODS The starting dose of febuxostat and allopurinol was 10 and 100 mg/d, respectively, and was increased to the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS